Background:

Cromolyn sodium is an antiallergic drug. Cromolyn sodium is a GSK-3β inhibitor with an IC50 of 2.0 μM.

Cromolyn (sodium) is a chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack.

Pretreatment of IIR mice with Cromolyn (sodium) prior to ischemia exhibited no changes of ET-1 levels, injury score and inflammation (P>0.05, PreCr vs. M groups). In conclusion, administration of Cromolyn (sodium) after reperfusion, but not prior to ischemia, attenuates IIRI by downregulating ET-1 and suppressing sustained MC activation[1]. Cromolyn (sodium) has a role in the prevention of Chronic lung disease(CLD). Cromolyn (sodium) cannot be recommended for the prevention of CLD in preterm infants[2].

参考文献:
[1]. Gan, X., et al., Treatment of mice with cromolyn sodium after reperfusion, but not prior to ischemia, attenuates small intestinal ischemia-reperfusion injury. Mol Med Rep, 2013. 8(3): p. 928-34.
[2]. Huang L, et al. Sinomenine-induced histamine release-like anaphylactoid reactions are blocked by tranilast via inhibiting NF-κB signaling. Pharmacol Res. 2017 Aug 31. pii: S1043-6618(17)30796-X.
[3]. Ng, G. and A. Ohlsson, Cromolyn sodium for the prevention of chronic lung disease in preterm infants. Cochrane Database Syst Rev, 2012. 6: p. CD003059.